Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of “Buy” by Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the company, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $29.29.

A number of equities research analysts have recently weighed in on the company. Wedbush restated an “outperform” rating and set a $29.00 target price on shares of Oculis in a research report on Wednesday, March 6th. HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Oculis in a report on Thursday, February 29th. Chardan Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of Oculis in a report on Tuesday, March 19th. Finally, Robert W. Baird dropped their price objective on Oculis from $64.00 to $35.00 and set an “outperform” rating for the company in a report on Tuesday, March 19th.

Oculis Stock Performance

OCS stock opened at $12.03 on Tuesday. Oculis has a twelve month low of $9.05 and a twelve month high of $14.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.29 and a current ratio of 5.29. The business has a fifty day moving average of $11.97 and a 200-day moving average of $11.20.

Oculis (NASDAQ:OCS) last released its earnings results on Monday, March 18th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.04. The firm had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.28 million. As a group, equities research analysts predict that Oculis will post -1.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oculis

Several large investors have recently modified their holdings of the business. abrdn plc bought a new stake in shares of Oculis in the fourth quarter worth about $15,980,000. Compagnie Lombard Odier SCmA increased its holdings in shares of Oculis by 47.3% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after acquiring an additional 30,750 shares in the last quarter. HRT Financial LP acquired a new position in shares of Oculis during the first quarter worth about $178,000. Ergoteles LLC acquired a new position in shares of Oculis during the second quarter worth about $247,000. Finally, Searle & CO. acquired a new position in shares of Oculis during the fourth quarter worth about $112,000. 22.30% of the stock is currently owned by institutional investors.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.